rufloxacin

Rufloxacin is a long-acting fluoroquinolone antibiotic used primarily for the treatment of susceptible respiratory tract and urinary tract infections. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV—enzymes essential for bacterial DNA replication and transcription—resulting in broad-spectrum antibacterial activity against various Gram-negative and Gram-positive bacteria. Rufloxacin is administered orally and has been marketed under several brand names in different countries. Its development originated with Mediolanum; other companies involved include Bracco, Hilton Pharma, Laboratoires Leurquin-Mediolanum, Selvi Laboratorio Bioterapico, and Universal Pharma Holdings.

Brand names

RufloxUrofloxMonosQariTebraxinUroclar

Other names

Chiriax